Jemal A, Siegel R, Ward E et al.. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.

• PubMed
JemalASiegelRWardE. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249. )| false
• Search Google Scholar
• Export Citation

Cooperberg MR, Lubeck DP, Meng MV et al.. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004;22:2141–2149.

• PubMed
CooperbergMRLubeckDPMengMV. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004;22:2141–2149. )| false
• Search Google Scholar
• Export Citation

Andriole GL, Crawford ED, Grubb RL III et al.. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–1319.

• PubMed
AndrioleGLCrawfordEDGrubbRLIII. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–1319. )| false
• Search Google Scholar
• Export Citation

Schroder FH, Hugosson J, Roobol MJ et al.. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–1328.

• PubMed
SchroderFHHugossonJRoobolMJ. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–1328. )| false
• Search Google Scholar
• Export Citation

Social Security Administration. Period Life Table. Available at: http://www.ssa.gov/OACT/STATS/table4c6.html. Accessed January 5, 2010.

• PubMed
Social Security Administration. Period Life Table. Available at: http://www.ssa.gov/OACT/STATS/table4c6.html. Accessed January 5, 2010. )| false
• Search Google Scholar
• Export Citation

Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006;295:801–808.

• PubMed
LeeSJLindquistKSegalMRCovinskyKE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006;295:801–808. )| false
• Search Google Scholar
• Export Citation

D'Amico AV, Whittington R, Malkowicz SB et al.. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17:168–172.

• PubMed
D'AmicoAVWhittingtonRMalkowiczSB. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17:168–172. )| false
• Search Google Scholar
• Export Citation

D'Amico AV, Whittington R, Malkowicz SB et al.. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002;95:281–286.

• PubMed
D'AmicoAVWhittingtonRMalkowiczSB. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002;95:281–286. )| false
• Search Google Scholar
• Export Citation

D'Amico AV, Whittington R, Malkowicz SB et al.. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–974.

• PubMed
D'AmicoAVWhittingtonRMalkowiczSB. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–974. )| false
• Search Google Scholar
• Export Citation

James Buchanan Brady Urological Institute. Johns Hopkins Medicine. The Partin Tables. Available at: http://urology.jhu.edu/prostate/partintables.php. Accessed January 5, 2010.

• PubMed
James Buchanan Brady Urological Institute. Johns Hopkins Medicine. The Partin Tables. Available at: http://urology.jhu.edu/prostate/partintables.php. Accessed January 5, 2010. )| false
• Search Google Scholar
• Export Citation

Makarov DV, Trock BJ, Humphreys EB et al.. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:1095–1101.

• PubMed
MakarovDVTrockBJHumphreysEB. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:1095–1101. )| false
• Search Google Scholar
• Export Citation

Kattan MW, Eastham JA, Wheeler TM et al.. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:1792–1797.

• PubMed
KattanMWEasthamJAWheelerTM. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:1792–1797. )| false
• Search Google Scholar
• Export Citation

Memorial Sloan-Kettering Cancer Center. Prostate Cancer Nomograms. Available at: http://www.mskcc.org/mskcc/html/10088.cfm. Accessed January 5, 2010.

• PubMed
Memorial Sloan-Kettering Cancer Center. Prostate Cancer Nomograms. Available at: http://www.mskcc.org/mskcc/html/10088.cfm. Accessed January 5, 2010. )| false
• Search Google Scholar
• Export Citation

Stephenson AJ, Scardino PT, Eastham JA et al.. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715–717.

• PubMed
StephensonAJScardinoPTEasthamJA. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715–717. )| false
• Search Google Scholar
• Export Citation

Stephenson AJ, Kattan MW, Eastham JA et al.. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300–4305.

• PubMed
StephensonAJKattanMWEasthamJA. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300–4305. )| false
• Search Google Scholar
• Export Citation

Graefen M, Haese A, Pichlmeier U et al.. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 2001;165:857–863.

• PubMed
GraefenMHaeseAPichlmeierU. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 2001;165:857–863. )| false
• Search Google Scholar
• Export Citation

Ohori M, Kattan MW, Koh H et al.. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004;171:1844–1849; discussion 1849.

• PubMed
OhoriMKattanMWKohH. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004;171:1844–1849; discussion 1849. )| false
• Search Google Scholar
• Export Citation

Steuber T, Graefen M, Haese A et al.. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol 2006;175:939–944; discussion 944.

• PubMed
SteuberTGraefenMHaeseA. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol 2006;175:939–944; discussion 944. )| false
• Search Google Scholar
• Export Citation

Briganti A, Chun FK, Salonia A et al.. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol 2007;51:112–119; discussion 119–120.

• PubMed
BrigantiAChunFKSaloniaA. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol 2007;51:112–119; discussion 119–120. )| false
• Search Google Scholar
• Export Citation

Kattan MW, Potters L, Blasko JC et al.. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393–399.

• PubMed
KattanMWPottersLBlaskoJC. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393–399. )| false
• Search Google Scholar
• Export Citation

Potters L, Morgenstern C, Calugaru E et al.. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2008;179:S20–24.

• PubMed
PottersLMorgensternCCalugaruE. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2008;179:S20–24. )| false
• Search Google Scholar
• Export Citation

Zelefsky MJ, Kattan MW, Fearn P et al.. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology 2007;70:283–287.

• PubMed
ZelefskyMJKattanMWFearnP. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology 2007;70:283–287. )| false
• Search Google Scholar
• Export Citation

Jeldres C, Suardi N, Walz J et al.. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008;54:1306–1313.

• PubMed
JeldresCSuardiNWalzJ. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008;54:1306–1313. )| false
• Search Google Scholar
• Export Citation

Stephenson AJ, Scardino PT, Kattan MW et al.. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035–2041.

• PubMed
StephensonAJScardinoPTKattanMW. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035–2041. )| false
• Search Google Scholar
• Export Citation

Dearnaley DP, Khoo VS, Norman AR et al.. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267–272.

• PubMed
DearnaleyDPKhooVSNormanAR. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267–272. )| false
• Search Google Scholar
• Export Citation

Khoo VS. Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy. Clin Oncol (R Coll Radiol) 2005;17:560–571.

• PubMed
KhooVS. Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy. Clin Oncol (R Coll Radiol) 2005;17:560–571. )| false
• Search Google Scholar
• Export Citation

D'Amico AV, Cote K, Loffredo M et al.. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:4567–4573.

• PubMed
D'AmicoAVCoteKLoffredoM. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:4567–4573. )| false
• Search Google Scholar
• Export Citation

D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125–135.

• PubMed
D'AmicoAVChenMHRoehlKACatalonaWJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125–135. )| false
• Search Google Scholar
• Export Citation

D'Amico AV, Moul JW, Carroll PR et al.. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376–1383.

• PubMed
D'AmicoAVMoulJWCarrollPR. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376–1383. )| false
• Search Google Scholar
• Export Citation

Sakr WA, Grignon DJ, Crissman JD et al.. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439–443.

• PubMed
SakrWAGrignonDJCrissmanJD. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439–443. )| false
• Search Google Scholar
• Export Citation

Thompson IM, Pauler DK, Goodman PJ et al.. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239–2246.

• PubMed
ThompsonIMPaulerDKGoodmanPJ. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239–2246. )| false
• Search Google Scholar
• Export Citation

Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165–8169.

• PubMed
KlotzL. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165–8169. )| false
• Search Google Scholar
• Export Citation

Draisma G, Etzioni R, Tsodikov A et al.. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374–383.

• PubMed
DraismaGEtzioniRTsodikovA. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374–383. )| false
• Search Google Scholar
• Export Citation

Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368–374.

• PubMed
EpsteinJIWalshPCCarmichaelMBrendlerCB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368–374. )| false
• Search Google Scholar
• Export Citation

Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004;101:2001–2005.

• PubMed
BastianPJMangoldLAEpsteinJIPartinAW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004;101:2001–2005. )| false
• Search Google Scholar
• Export Citation

Chun FK, Haese A, Ahyai SA et al.. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 2008;113:701–709.

• PubMed
ChunFKHaeseAAhyaiSA. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 2008;113:701–709. )| false
• Search Google Scholar
• Export Citation

Bastian PJ, Carter BH, Bjartell A et al.. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009;55:1321–1330.

• PubMed
BastianPJCarterBHBjartellA. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009;55:1321–1330. )| false
• Search Google Scholar
• Export Citation

Draisma G, Boer R, Otto SJ et al.. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–878.

• PubMed
DraismaGBoerROttoSJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–878. )| false
• Search Google Scholar
• Export Citation

Lu-Yao GL, Albertsen PC, Moore DF et al.. Outcomes of localized prostate cancer following conservative management. JAMA 2009;302:1202–1209.

• PubMed
Lu-YaoGLAlbertsenPCMooreDF. Outcomes of localized prostate cancer following conservative management. JAMA 2009;302:1202–1209. )| false
• Search Google Scholar
• Export Citation

Sanda MG, Kaplan ID. A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. JAMA 2009;301:2141–2151.

• PubMed
SandaMGKaplanID. A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. JAMA 2009;301:2141–2151. )| false
• Search Google Scholar
• Export Citation

Shappley WV III, Kenfield SA, Kasperzyk JL et al.. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009;27:4980–4985.

• PubMed
ShappleyWVIIIKenfieldSAKasperzykJL. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009;27:4980–4985. )| false
• Search Google Scholar
• Export Citation

Bill-Axelson A, Holmberg L, Filen F et al.. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100:1144–1154.

• PubMed
Bill-AxelsonAHolmbergLFilenF. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100:1144–1154. )| false
• Search Google Scholar
• Export Citation

Schroder FH, Roach M III, Scardino P. Clinical decisions. Management of prostate cancer. N Engl J Med 2008;359:2605–2609.

• PubMed
SchroderFHRoachMIIIScardinoP. Clinical decisions. Management of prostate cancer. N Engl J Med 2008;359:2605–2609. )| false
• Search Google Scholar
• Export Citation

Schwartz RS. Clinical decisions. Management of prostate cancer—polling results. N Engl J Med 2009;360:e4.

• PubMed
SchwartzRS. Clinical decisions. Management of prostate cancer—polling results. N Engl J Med 2009;360:e4. )| false
• Search Google Scholar
• Export Citation

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997;79:235–246.

• PubMed
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997;79:235–246. )| false
• Search Google Scholar
• Export Citation

Carter HB, Kettermann A, Warlick C et al.. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178:2359–2364; discussion 2364–2355.

• PubMed
CarterHBKettermannAWarlickC. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178:2359–2364; discussion 2364–2355. )| false
• Search Google Scholar
• Export Citation

Choo R, Klotz L, Danjoux C et al.. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002;167:1664–1669.

• PubMed
ChooRKlotzLDanjouxC. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002;167:1664–1669. )| false
• Search Google Scholar
• Export Citation

Stephenson AJ, Aprikian AG, Souhami L et al.. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002;59:652–656.

• PubMed
StephensonAJAprikianAGSouhamiL. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002;59:652–656. )| false
• Search Google Scholar
• Export Citation

van den Bergh RC, Essink-Bot ML, Roobol MJ et al.. Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009;115:3868–3878.

• PubMed
van den BerghRCEssink-BotMLRoobolMJ. Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009;115:3868–3878. )| false
• Search Google Scholar
• Export Citation

Hanlon AL, Watkins Bruner D, Peter R, Hanks GE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 2001;49:51–59.

• PubMed
HanlonALWatkins BrunerDPeterRHanksGE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 2001;49:51–59. )| false
• Search Google Scholar
• Export Citation

Koper PC, Stroom JC, van Putten WL et al.. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 1999;43:727–734.

• PubMed
KoperPCStroomJCvan PuttenWL. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 1999;43:727–734. )| false
• Search Google Scholar
• Export Citation

Michalski JM, Bae K, Roach M et al.. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 2010;76:14–22.

• PubMed
MichalskiJMBaeKRoachM. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 2010;76:14–22. )| false
• Search Google Scholar
• Export Citation

Peeters ST, Heemsbergen WD, Koper PC et al.. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990–1996.

• PubMed
PeetersSTHeemsbergenWDKoperPC. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990–1996. )| false
• Search Google Scholar
• Export Citation

Pollack A, Zagars GK, Starkschall G et al.. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097–1105.

• PubMed
PollackAZagarsGKStarkschallG. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097–1105. )| false
• Search Google Scholar
• Export Citation

Zietman AL, DeSilvio ML, Slater JD et al.. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233–1239.

• PubMed
ZietmanALDeSilvioMLSlaterJD. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233–1239. )| false
• Search Google Scholar
• Export Citation

Kuban DA, Tucker SL, Dong L et al.. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74.

• PubMed
KubanDATuckerSLDongL. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74. )| false
• Search Google Scholar
• Export Citation

Potosky AL, Davis WW, Hoffman RM et al.. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:1358–1367.

• PubMed
PotoskyALDavisWWHoffmanRM. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:1358–1367. )| false
• Search Google Scholar
• Export Citation

D'Amico AV, Manola J, Loffredo M et al.. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821–827.

• PubMed
D'AmicoAVManolaJLoffredoM. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821–827. )| false
• Search Google Scholar
• Export Citation

Sanda MG, Dunn RL, Michalski J et al.. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–1261.

• PubMed
SandaMGDunnRLMichalskiJ. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–1261. )| false
• Search Google Scholar
• Export Citation

Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 2007;110:1417–1428.

• PubMed
NguyenPLD'AmicoAVLeeAKSuhWW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 2007;110:1417–1428. )| false
• Search Google Scholar
• Export Citation

Merrick GS, Butler WM, Wallner KE et al.. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 2004;64:754–759.

• PubMed
MerrickGSButlerWMWallnerKE. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 2004;64:754–759. )| false
• Search Google Scholar
• Export Citation

D'Amico AV, Moran BJ, Braccioforte MH et al.. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009;27:3923–3928.

• PubMed
D'AmicoAVMoranBJBraccioforteMH. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009;27:3923–3928. )| false
• Search Google Scholar
• Export Citation

Nag S, Bice W, DeWyngaert K et al.. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000;46:221–230.

• PubMed
NagSBiceWDeWyngaertK. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000;46:221–230. )| false
• Search Google Scholar
• Export Citation

Hartsell WF, Scott CB, Bruner DW et al.. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97:798–804.

• PubMed
HartsellWFScottCBBrunerDW. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97:798–804. )| false
• Search Google Scholar
• Export Citation

Konski A, James J, Hartsell W et al.. Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. Am J Clin Oncol 2009;32:423–428.

• PubMed
KonskiAJamesJHartsellW. Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. Am J Clin Oncol 2009;32:423–428. )| false
• Search Google Scholar
• Export Citation

Janjan N, Lutz ST, Bedwinek JM et al.. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med 2009;12:417–426.

• PubMed
JanjanNLutzSTBedwinekJM. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med 2009;12:417–426. )| false
• Search Google Scholar
• Export Citation

Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004;45:1358–1365.

• PubMed
Pandit-TaskarNBatrakiMDivgiCR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004;45:1358–1365. )| false
• Search Google Scholar
• Export Citation

Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095–2101.

• PubMed
AlbertsenPCHanleyJAFineJ. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095–2101. )| false
• Search Google Scholar
• Export Citation

Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975–980.

• PubMed
AlbertsenPCHanleyJAGleasonDFBarryMJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975–980. )| false
• Search Google Scholar
• Export Citation

Herrell SD, Smith JA Jr. Robotic-assisted laparoscopic prostatectomy: what is the learning curve? Urology 2005;66:105–107.

• PubMed
HerrellSDSmithJAJr. Robotic-assisted laparoscopic prostatectomy: what is the learning curve? Urology 2005;66:105–107. )| false
• Search Google Scholar
• Export Citation

Smith JA Jr, Herrell SD. Robotic-assisted laparoscopic prostatectomy: do minimally invasive approaches offer significant advantages? J Clin Oncol 2005;23:8170–8175.

• PubMed
SmithJAJrHerrellSD. Robotic-assisted laparoscopic prostatectomy: do minimally invasive approaches offer significant advantages? J Clin Oncol 2005;23:8170–8175. )| false
• Search Google Scholar
• Export Citation

Hu JC, Gu X, Lipsitz SR et al.. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009;302:1557–1564.

• PubMed
HuJCGuXLipsitzSR. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009;302:1557–1564. )| false
• Search Google Scholar
• Export Citation

Abel EJ, Masterson TA, Warner JN et al.. Nerve-sparing prostatectomy and urinary function: a prospective analysis using validated quality-of-life measures. Urology 2009;73:1336–1340.

• PubMed
AbelEJMastersonTAWarnerJN. Nerve-sparing prostatectomy and urinary function: a prospective analysis using validated quality-of-life measures. Urology 2009;73:1336–1340. )| false
• Search Google Scholar
• Export Citation

Davis JW, Chang DW, Chevray P et al.. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol 2009;55:1135–1143.

• PubMed
DavisJWChangDWChevrayP. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol 2009;55:1135–1143. )| false
• Search Google Scholar
• Export Citation

Cagiannos I, Karakiewicz P, Eastham JA et al.. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003;170:1798–1803.

• PubMed
CagiannosIKarakiewiczPEasthamJA. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003;170:1798–1803. )| false
• Search Google Scholar
• Export Citation

Masterson TA, Bianco FJ Jr, Vickers AJ et al.. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006;175:1320–1324; discussion 1324–1325.

• PubMed
MastersonTABiancoFJJrVickersAJ. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006;175:1320–1324; discussion 1324–1325. )| false
• Search Google Scholar
• Export Citation

Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006;68:121–125.

• PubMed
JoslynSAKonetyBR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006;68:121–125. )| false
• Search Google Scholar
• Export Citation

Allaf ME, Palapattu GS, Trock BJ et al.. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004;172:1840–1844.

• PubMed
AllafMEPalapattuGSTrockBJ. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004;172:1840–1844. )| false
• Search Google Scholar
• Export Citation

Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849–854.

• PubMed
BaderPBurkhardFCMarkwalderRStuderUE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849–854. )| false
• Search Google Scholar
• Export Citation

Daneshmand S, Quek ML, Stein JP et al.. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004;172:2252–2255.

• PubMed
DaneshmandSQuekMLSteinJP. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004;172:2252–2255. )| false
• Search Google Scholar
• Export Citation

Wagner M, Sokoloff M, Daneshmand S. The role of pelvic lymphadenectomy for prostate cancer—therapeutic? J Urol 2008;179:408–413.

• PubMed
WagnerMSokoloffMDaneshmandS. The role of pelvic lymphadenectomy for prostate cancer—therapeutic? J Urol 2008;179:408–413. )| false
• Search Google Scholar
• Export Citation

Labrie F, Dupont A, Belanger A, Lachance R. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 1987;138:804–806.

• PubMed
LabrieFDupontABelangerALachanceR. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 1987;138:804–806. )| false
• Search Google Scholar
• Export Citation

Schulze H, Senge T. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 1990;144:934–941.

• PubMed
SchulzeHSengeT. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 1990;144:934–941. )| false
• Search Google Scholar
• Export Citation

Iversen P, Johansson JE, Lodding P et al.. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol 2006;40:441–452

• PubMed
IversenPJohanssonJELoddingP. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol 2006;40:441–452 )| false
• Search Google Scholar
• Export Citation

Bolla M, Collette L, Blank L et al.. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103–106.

• PubMed
BollaMColletteLBlankL. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103–106. )| false
• Search Google Scholar
• Export Citation

Kumar S, Shelley M, Harrison C et al.. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;(4):CD006019.

• PubMed
KumarSShelleyMHarrisonC. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;(4):CD006019. )| false
• Search Google Scholar
• Export Citation

Shelley MD, Kumar S, Wilt T et al.. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35:9–17.

• PubMed
ShelleyMDKumarSWiltT. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35:9–17. )| false
• Search Google Scholar
• Export Citation

Bolla M, Gonzalez D, Warde P et al.. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295–300.

• PubMed
BollaMGonzalezDWardeP. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295–300. )| false
• Search Google Scholar
• Export Citation

Denham JW, Steigler A, Lamb DS et al.. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841–850.

• PubMed
DenhamJWSteiglerALambDS. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841–850. )| false
• Search Google Scholar
• Export Citation

Loblaw DA, Virgo KS, Nam R et al.. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596–1605.

• PubMed
LoblawDAVirgoKSNamR. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596–1605. )| false
• Search Google Scholar
• Export Citation

Messing EM, Manola J, Yao J et al.. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472–479.

• PubMed
MessingEMManolaJYaoJ. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472–479. )| false
• Search Google Scholar
• Export Citation

Wong YN, Freedland S, Egleston B et al.. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2009;27:100–105.

• PubMed
WongYNFreedlandSEglestonB. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2009;27:100–105. )| false
• Search Google Scholar
• Export Citation

McLeod DG, Iversen P, See WA et al.. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97:247–254.

• PubMed
McLeodDGIversenPSeeWA. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97:247–254. )| false
• Search Google Scholar
• Export Citation

McLeod DG, See WA, Klimberg I et al.. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol 2006;176:75–80.

• PubMed
McLeodDGSeeWAKlimbergI. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol 2006;176:75–80. )| false
• Search Google Scholar
• Export Citation

Lu-Yao GL, Albertsen PC, Moore DF et al.. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173–181.

• PubMed
Lu-YaoGLAlbertsenPCMooreDF. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173–181. )| false
• Search Google Scholar
• Export Citation

Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008;358:1474–1482.

• PubMed
EbelingPR. Clinical practice. Osteoporosis in men. N Engl J Med 2008;358:1474–1482. )| false
• Search Google Scholar
• Export Citation

Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154–164.

• PubMed
ShahinianVBKuoYFFreemanJLGoodwinJS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154–164. )| false
• Search Google Scholar
• Export Citation

Smith MR, Boyce SP, Moyneur E et al.. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006;175:136–139; discussion 139.

• PubMed
SmithMRBoyceSPMoyneurE. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006;175:136–139; discussion 139. )| false
• Search Google Scholar
• Export Citation

Smith MR, Lee WC, Brandman J et al.. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897–7903.

• PubMed
SmithMRLeeWCBrandmanJ. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897–7903. )| false
• Search Google Scholar
• Export Citation

Daniell HW, Dunn SR, Ferguson DW et al.. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181–186.

• PubMed
DaniellHWDunnSRFergusonDW. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181–186. )| false
• Search Google Scholar
• Export Citation

Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998;83:1561–1566.

• PubMed
DiamondTCampbellJBryantCLynchW. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998;83:1561–1566. )| false
• Search Google Scholar
• Export Citation

Maillefert JF, Sibilia J, Michel F et al.. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219–1222.

• PubMed
MaillefertJFSibiliaJMichelF. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219–1222. )| false
• Search Google Scholar
• Export Citation

Smith MR, McGovern FJ, Zietman AL et al.. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948–955.